Quarterly ResultMay 5, 2026, 04:10 PM
IDEAYA Biosciences Q1 Net Loss $(98.5)M; Revenue $6.56M
AI Summary
IDEAYA Biosciences reported a net loss of $(98.5) million for Q1 2026, an increase from $(72.2) million in Q1 2025, with a net loss per share of $(1.11). The company generated its first collaboration revenue of $6.56 million during the quarter. As of March 31, 2026, IDEAYA held $972.9 million in cash, cash equivalents, and marketable securities, which management believes is sufficient to fund operations for at least 12 months.
Key Highlights
- Q1 2026 net loss was $(98.5) million, compared to $(72.2) million in Q1 2025.
- Net loss per share for Q1 2026 was $(1.11), up from $(0.82) in Q1 2025.
- Collaboration revenue for Q1 2026 was $6.56 million, up from $0 in Q1 2025.
- Research and development expenses rose to $95.7 million from $70.9 million year-over-year.
- Cash, cash equivalents, and marketable securities totaled $972.9 million as of March 31, 2026.
- Net cash used in operating activities was $(75.2) million, up from $(60.3) million year-over-year.
- Amended South San Francisco facility lease to add 24,909 sq ft, commencing Q1 2027.